Outgoing OGD Director Outlines Accomplishments During His Tenure
Executive Summary
Gregory Geba highlights the strides the Office of Generic Drugs made in implementing the generic drug user fee program in his resignation announcement.
You may also be interested in...
ANDA Pre-Submission Meetings Being Considered By FDA
Designed to boost application quality, creating such meetings would be another sign of the evolution of the Office of Generic Drugs.
FDA Generics Director’s Departure Shows Why Chemistry Matters
Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.
FDA Generics Director’s Departure Shows Why Chemistry Matters
Another outside candidate is expected to eventually take over for the departing director Gregory Geba, and while the Office of Generic Drugs can run smoothly without a permanent leader for now, it cannot do so forever.